Metformin in Patients With Type 2 Diabetes and Kidney Disease

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Metformin is widely viewed as the best initial pharmacological option to lower glucose concentrations in patients with type 2 diabetes mellitus. However, the drug is contraindicated in many individuals with impaired kidney function because of concerns of lactic acidosis.

Related collections

Author and article information

Journal

Title: JAMA

Abbreviated Title: JAMA

Publisher: American Medical Association (AMA)

ISSN (Print): 0098-7484

Publication date Created: December 24 2014

Publication date (Print): December 24 2014

Volume: 312

Issue: 24

Page: 2668

Affiliations

[1 ]Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut

[2 ]Health Sciences Digital Library and Learning Center, University of Texas Southwestern Medical Center, Dallas

[3 ]School of Life & Health Sciences, Aston University, Birmingham, United Kingdom

[4 ]Division of Cardiology, University of Texas Southwestern Medical Center, Dallas

Article

DOI: 10.1001/jama.2014.15298

PubMed ID: 25536258

SO-VID: 050235e6-7977-498e-b72d-9a08ac5ccebe

History

Data availability:

Comments

Comment on this article

scite_

Cited by 188

See all cited by

- Version 1

Metformin in Patients With Type 2 Diabetes and Kidney Disease : A Systematic Review

Read this article at